Nuvalent Inc
NUVL77.160USD
-0.600-0.77%
Horário de mercado （ET）Cotações atrasadas em 15 min
5.54BValor de mercado
PerdaP/L TTM
Mais detalhes de Nuvalent Inc Empresa
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.
Informações da empresa
Código da empresaNUVL
Nome da EmpresaNuvalent Inc
Data de listagemJul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
Número de funcionários142
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 29
EndereçoOne Broadway, 14Th Floor
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Telefone18573577000
Sitehttps://www.nuvalent.com/
Código da empresaNUVL
Data de listagemJul 29, 2021
CEODr. James R. (Jim) Porter, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
2.65K
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.64M
+0.16%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
60.96K
-3.40%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
20.78K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
7.08K
--
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+105.92%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.97K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
Investidores
Investidores
Proporção
Deerfield Management Company, L.P.
27.11%
Fidelity Management & Research Company LLC
14.61%
Paradigm BioCapital Advisors LP
7.94%
The Vanguard Group, Inc.
6.68%
BlackRock Institutional Trust Company, N.A.
4.11%
Other
39.55%
Tipos de investidores
Investidores
Proporção
Hedge Fund
48.82%
Investment Advisor
35.80%
Investment Advisor/Hedge Fund
19.30%
Individual Investor
2.87%
Private Equity
2.46%
Research Firm
1.99%
Venture Capital
0.77%
Sovereign Wealth Fund
0.48%
Pension Fund
0.25%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
438
74.96M
112.94%
-1.46M
2025Q1
443
75.23M
113.38%
-1.51M
2024Q4
428
73.56M
111.20%
-2.43M
2024Q3
401
72.99M
113.51%
-264.12K
2024Q2
367
68.27M
114.85%
-2.37M
2024Q1
344
66.52M
113.46%
-4.79M
2023Q4
296
66.77M
116.76%
+1.56M
2023Q3
249
58.89M
114.16%
-3.80M
2023Q2
230
58.54M
113.63%
-2.82M
2023Q1
202
57.17M
111.42%
-2.69M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Deerfield Management Company, L.P.
17.99M
27.11%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
9.70M
14.61%
+99.92K
+1.04%
Mar 31, 2025
Paradigm BioCapital Advisors LP
5.27M
7.94%
-93.95K
-1.75%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
6.68%
-60.03K
-1.34%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.73M
4.11%
-65.91K
-2.36%
Mar 31, 2025
Commodore Capital LP
1.85M
2.79%
+233.40K
+14.39%
Mar 31, 2025
Shair (Matthew)
1.64M
2.48%
+2.65K
+0.16%
Jun 18, 2025
Perceptive Advisors LLC
1.63M
2.46%
-986.01K
-37.63%
Mar 31, 2025
Bain Capital Life Sciences Investors, LLC
1.45M
2.18%
--
--
Mar 31, 2025
Wellington Management Company, LLP
1.44M
2.17%
+157.81K
+12.28%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Tema Oncology ETF
3.99%
ALPS Medical Breakthroughs ETF
3.42%
Global X Guru Index ETF
1.27%
SPDR S&P Biotech ETF
0.93%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
ProShares Ultra Nasdaq Biotechnology
0.56%
Invesco Nasdaq Biotechnology ETF
0.56%
iShares Health Innovation Active ETF
0.54%
Direxion Daily S&P Biotech Bull 3X Shares
0.53%
iShares Biotechnology ETF
0.35%
Ver Mais
Tema Oncology ETF
Proporção3.99%
ALPS Medical Breakthroughs ETF
Proporção3.42%
Global X Guru Index ETF
Proporção1.27%
SPDR S&P Biotech ETF
Proporção0.93%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.88%
ProShares Ultra Nasdaq Biotechnology
Proporção0.56%
Invesco Nasdaq Biotechnology ETF
Proporção0.56%
iShares Health Innovation Active ETF
Proporção0.54%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.53%
iShares Biotechnology ETF
Proporção0.35%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
